Cytokinetics Incorporated

27.88-1.58-5.36%Vol 1.33M1Y Perf -39.20%
Oct 2nd, 2023 16:00 DELAYED
BID27.00 ASK29.07
Open29.36 Previous Close29.46
Pre-Market- After-Market27.88
 - -  - -%
Target Price
62.36 
Analyst Rating
Strong Buy 1.29
Potential %
123.67 
Finscreener Ranking
★+     44.45
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     40.03
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     40.73
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
-4.61 
Earnings Rating
Strong Buy
Market Cap2.68B 
Earnings Date
2nd Nov 2023
Alpha0.03 Standard Deviation0.16
Beta0.74 

Today's Price Range

27.5629.40

52W Range

28.9652.40

5 Year PE Ratio Range

-8.8050.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.07%
1 Month
-22.56%
3 Months
-16.43%
6 Months
-26.07%
1 Year
-39.20%
3 Years
16.22%
5 Years
200.11%
10 Years
296.59%

TickerPriceChg.Chg.%
CYTK27.88-1.5800-5.36
AAPL173.752.54001.48
GOOG135.173.32002.52
MSFT321.806.05001.92
XOM115.63-1.9500-1.66
WFC39.61-1.2500-3.06
JNJ155.15-0.6000-0.39
FB196.640.99000.51
GE108.79-1.7600-1.59
JPM143.77-1.2500-0.86
Financial StrengthValueIndustryS&P 500US Markets
11.40
11.60
0.74
2.91
-5.50
Leverage Ratio 13.40
ProfitabilityValueIndustryS&P 500US Markets
-241.80
-161.10
-157.80
-405.90
-99.17
RevenueValueIndustryS&P 500US Markets
92.63M
0.98
30.92
12.23
Earnings HistoryEstimateReportedSurprise %
Q02 2023-1.23-1.34-8.94
Q01 2023-1.24-1.38-11.29
Q04 2022-1.22-1.45-18.85
Q03 2022-1.19-1.28-7.56
Q02 2022-1.04-0.2377.88
Q01 2022-0.93-1.02-9.68
Q04 2021-0.89-0.3659.55
Q03 2021-0.75-0.95-26.67
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.7230.10Positive
12/2023 QR-0.757.41Positive
12/2023 FY-4.106.39Positive
12/2024 FY-3.8110.77Positive
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.72
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume1.33M
Shares Outstanding96.00K
Shares Float92.35M
Trades Count18.11K
Dollar Volume37.53M
Avg. Volume878.27K
Avg. Weekly Volume1.11M
Avg. Monthly Volume794.55K
Avg. Quarterly Volume733.80K

Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 27.88 per share at the end of the most recent trading day (a -5.36% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 2.68B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.

The one-year performance of Cytokinetics Incorporated stock is -39.2%, while year-to-date (YTD) performance is -39.15%. CYTK stock has a five-year performance of 200.11%. Its 52-week range is between 28.96 and 52.4013, which gives CYTK stock a 52-week price range ratio of -4.61%

Cytokinetics Incorporated currently has a PE ratio of -13.80, a price-to-book (PB) ratio of 31.90, a price-to-sale (PS) ratio of 43.21, a price to cashflow ratio of 409.20, a PEG ratio of -, a ROA of -31.76%, a ROC of -39.38% and a ROE of -289.41%. The company’s profit margin is -99.17%, its EBITDA margin is -157.80%, and its revenue ttm is $92.63 Million , which makes it $0.98 revenue per share.

Of the last four earnings reports from Cytokinetics Incorporated, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.29), with a target price of $62.36, which is +123.67% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cytokinetics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 9.79, ATR14 : 1.32, CCI20 : -138.05, Chaikin Money Flow : -0.33, MACD : -1.33, Money Flow Index : 11.39, ROC : -18.50, RSI : 26.33, STOCH (14,3) : 4.15, STOCH RSI : 0.00, UO : 31.17, Williams %R : -95.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: Blum Robert (Option Excercise at a value of $2 107 200), Blum Robert (Sold 230 000 shares of value $8 906 725 ), Blum Robert I (Option Exercise at a value of $120 625), Blum Robert I (Sold 12 500 shares of value $463 250 ), Ching W. Jaw (Sold 0 shares of value $-181 500 ), Ching W. Jaw (Sold 15 000 shares of value $675 000 ), Fady I. Malik (Option Excercise at a value of $319 040), Fady I. Malik (Sold 66 300 shares of value $2 783 546 ), Fady Ibraham Malik (Option Excercise at a value of $263 320), Fady Ibraham Malik (Sold 52 513 shares of value $2 250 634 ), Henderson John (Option Excercise at a value of $28 245), Henderson John (Sold 4 166 shares of value $157 350 ), Robert C. Wong (Sold 7 338 shares of value $321 607 ), Robert I. Blum (Option Excercise at a value of $988 013), Robert I. Blum (Sold 107 500 shares of value $4 475 995 ), Wendall Wierenga (Option Excercise at a value of $87 494), Wendall Wierenga (Sold 13 020 shares of value $507 760 ), Wendell D. Wierenga (Option Excercise at a value of $47 040), Wendell D. Wierenga (Sold 7 000 shares of value $315 000 ), Wong Robert (Sold 7 338 shares of value $321 607 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (78.57 %)
13 (81.25 %)
12 (80.00 %)
Moderate Buy
2 (14.29 %)
2 (12.50 %)
2 (13.33 %)
Hold
1 (7.14 %)
1 (6.25 %)
1 (6.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.25
Strong Buy
1.27

Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

CEO: Robert I. Blum

Telephone: +1 650 624-3000

Address: 280 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

 

TipRanks News for CYTK

Mon, 25 Sep 2023 11:00 GMT Analysts Top Healthcare Picks: Cytokinetics (CYTK), Amgen (AMGN)

- TipRanks. All rights reserved.

Fri, 22 Sep 2023 10:31 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and CymaBay Therapeutics (CBAY)

- TipRanks. All rights reserved.

Fri, 28 Jul 2023 20:05 GMT Cytokinetics (CYTK) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits